- Borderline tumours of the ovary: Common practice in the Netherlands
- Accuracy of Intraoperative Computed Tomography in Deep Brain Stimulation-A Prospective Noninferiority Study
- BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
- Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
- The (R)-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the α-adrenoceptor
- Judging residents' performance: a qualitative study using grounded theory
- Twenty-nine Cases of Enterovirus-D68-associated Acute Flaccid Myelitis in Europe 2016 A Case Series and Epidemiologic Overview
- STAT3 Regulates the Onset of Oxidant-Induced Senescence in Lung Fibroblasts
- Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies
- Evaluation of Macitentan in Patients With Eisenmenger Syndrome Results From the Randomized, Controlled MAESTRO Study
Most Used Journals
Identification of 6-benzyloxysalicylates as a novel class of inhibitors of 15-lipoxygenase-1.
Eur J Med Chem. 2015 Mar 5;94:265-275
Authors: Eleftheriadis N, Thee S, Te Biesebeek J, van der Wouden P, Baas BJ, Dekker FJ
Lipoxygenases metabolize polyunsaturated fatty acids into signalling molecules such as leukotrienes and lipoxins. 15-lipoxygenase-1 (15-LOX-1) is an important mammalian lipoxygenase and plays a crucial regulatory role in several respiratory diseases such as asthma, COPD and chronic bronchitis. Novel potent and selective inhibitors of 15-LOX-1 are required to explore the role of this enzyme in drug discovery. In this study we describe structure activity relationships for 6-benzyloxysalicylates as inhibitors of human 15-LOX-1. Kinetic analysis suggests competitive inhibition and the binding model of these compounds can be rationalized using molecular modelling studies. The most potent derivative 37a shows a Ki value of 1.7 μM. These structure activity relationships provide a basis to design improved inhibitors and to explore 15-LOX-1 as a drug target.
PMID: 25771032 [PubMed – as supplied by publisher]